Want to stay in touch with the latest updates from Drug Development and Delivery? That's easy! Just subscribe clicking the Follow button below, choose topics or keywords for filtering if you want to, and we send the news to your inbox, to your phone via push notifications or we put them on your personal page here on follow.it.
Reading your RSS feed has never been easier!
Website title: Drug Development & Delivery - The Latest Methods in Drug Development
Is this your feed? Claim it!
Bioxytran, Inc. recently announced results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical study evaluating oral ProLectin-M in hospitalized patients with mild to moderate COVID-19 caused by SARS-CoV-2.
The study showed that the highest evaluated dose of ProLectin-M (16,800 mg/day) was associated with statistically significant earlier vira...
Quotient Sciences recently announced an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrod...
Neurizon Therapeutics Limited recently announced the first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon’s lead candidate, NUZ-001, for the treatment of amyotrophic lateral sclerosis (ALS).
The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) is a multicentre, double-blind, placebo-controlled adaptive...
MGS recently announced the acquisition of Knudsen Plast A/S, a premier Denmark-based injection molder with more than 40 years of dedicated healthcare manufacturing experience. With operations in both Denmark and Slovakia, the acquisition of Knudsen Plast A/S enhances MGS’ ability to support customer needs across Europe with expanded cleanroom capacity, deep injection molding ...
Protara Therapeutics, Inc. recently announced updated interim results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002, the Company’s investigational cell-based therapy, in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive or BCG-Naï...